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Background: The combination DTaP-IPV/Hib vaccine was licensed in the United States in 2008 for
children ages 6 weeks through 4 years with doses administered at 2, 4, 6, and 15–18 months of age.
The aim of this study was to assess the safety of DTaP-IPV/Hib vaccine routinely administered as part
of clinical care to infants at Kaiser Permanente Northern California.
Methods: This was an observational, retrospective study that included all 2-month-old infants vaccinated
with either DTaP-IPV/Hib or another DTaP-containing vaccine. We monitored all subjects for non-elective
hospitalizations, emergency department visits and selected outpatient outcomes (seizures, Guillain-Barré
Syndrome, encephalopathy, encephalitis, alteration of consciousness, meningitis, hypersensitivity reac-
tions, immune thrombocytopenic purpura, hemolytic anemia, type 1 diabetes, and Kawasaki disease)
beginning with their first dose through 6 months after a 4th dose or until 24 months of age. We calcu-
lated incidence rate ratios (IRRs) in the primary analysis by comparing rates of outcomes during the
post-vaccination risk interval with rates during a comparison interval more remote from vaccination.
Secondary analyses compared outcomes after DTaP-IPV/Hib with those after other DTaP-containing vac-
cines. We reviewed the medical records of selected outcomes.
Results: From October 1, 2008 through July 31, 2010, 14,042 subjects received a first dose of DTaP-IPV/
Hib, 13,194 received 2 doses, 12,548 received 3 doses and 6702 received 4 doses. Overall, there were
166 comparisons with significantly elevated IRRs and 165 comparisons with significantly reduced IRRs.
Medical record review of outcomes with significantly elevated IRRs in both the primary and secondary
analyses did not suggest any relationship with DTaP-IPV/Hib.
Conclusions: This study did not detect any safety concerns following DTaP-IPV/Hib and provides reassur-
ance that DTaP-IPV/Hib administered as part of routine care was not associated with unexpected safety
risks.
Conclusions: ClinicalTrials.gov Identifier: NCT00804284
 2016 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Combination vaccines offer a practical solution to the increasing
complexity of childhood immunization by simplifying implemen-
tation, increasing compliance with recommended immunization
schedules, increasing acceptance among healthcare providers and
parents, reducing the number of vaccine injections and avoiding
extra clinic visits, decreasing fear and pain among infants and
toddlers, reducing costs associated with stocking and administer-ing each of the individual vaccines, and facilitating the inclusion
of new vaccines in immunization programs. The Advisory Commit-
tee on Immunization Practices (ACIP), the American Academy of
Pediatrics, and the American Academy of Family Physicians recom-
mend and generally prefer combination vaccines to be used as
indicated for the child’s age [1].
The combination diphtheria, tetanus, pertussis, poliovirus types
1–3, and Haemophilus influenzae type b vaccine (DTaP-IPV/Hib;
Pentacel, Sanofi Pasteur, Swiftwater, PA) was licensed in the
United States in 2008 for children 6 weeks through 4 years of age
for use as a 4-dose schedule at 2, 4, 6, and 15–18 months of age
[2]. DTaP-IPV/Hib has been licensed in Canada since 1997, with
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48 million doses in the US).
Pre-licensure clinical trials evaluating DTaP-IPV/Hib demon-
strated comparable safety and immunogenicity with separate
administration of its component vaccines [3]. Following DTaP-
IPV/Hib licensure in the US, we conducted the current signal detec-
tion study to evaluate the safety of DTaP-IPV/Hib administered
routinely as part of clinical care to infants and toddlers.Table 1
Study groups.
Group Vaccines received
1 DTaP-IPV/Hib vaccine only (Pentacel, Sanofi Pasteur)
2 Daptacel (DTaP) vaccine only (Sanofi Pasteur)
3 Tripedia (DTaP) vaccine only (Sanofi Pasteur) for doses 1–3, and
either Tripedia or TriHIBit (DTaP-Hib) vaccine (Sanofi Pasteur) for
Dose 4
4 Infanrix (DTaP) vaccine only (GlaxoSmithKline)
5 Pediarix (DTaP-HBV-IPV) vaccine for doses 1–3 (GlaxoSmithKline),
and either Pediarix or Infanrix for Dose 4
6 Subjects who had more than one brand of DTaP vaccine or the brand
was unknown for at least one dose
DTaP: diphtheria, tetanus, and acellular pertussis vaccine; IPV: inactivated polio
vaccine; Hib: Haemophilus influenzae type b vaccine; HBV: hepatitis B vaccine.2. Methods
2.1. Study population
This Phase 4, retrospective, observational study was performed
as a post-licensure commitment to the US Food and Drug Admin-
istration. The study was conducted at Kaiser Permanente Northern
California (KPNC), an integrated healthcare organization that pro-
vides comprehensive medical care to approximately 3.3 million
members. KPNC has an approximate birth cohort of 35,000 per
year. KPNC maintains databases that capture all medical care
received by its members, including but not limited to all inpatient,
Emergency Department (ED), and outpatient clinic visits; immu-
nizations; and pharmacy and radiology data. We identified mortal-
ity data through state death reports and KPNC medical records.
We included all 2-month-old infants who received a
DTaP-containing vaccine as part of routine clinical care in KPNC.
This study began October 1, 2008 (the date DTaP-IPV/Hib was
introduced in KPNC) and accrued new infants until the first occur-
rence of either the end of the first study year or 10,000 infants who
had received DTaP-IPV/Hib vaccine for the primary series. We
followed all infants from the time of the first dose of a DTaP-
containing vaccine through either 6 months after their 4th dose,
or until 24 months of age, whichever occurred first.
2.2. Outcomes
We monitored vaccinees for all non-elective hospitalizations,
and all outcomes in ED setting. Only a limited number of pre-
selected outpatient outcomes recorded during the 30 day post-
vaccination risk interval were evaluated. The pre-specified outpa-
tient outcomes were seizures (post-vaccination days 0–3 only),
Guillain-Barré Syndrome, encephalopathy, encephalitis, alteration
of consciousness (other than secondary to another diagnosis),
meningitis, hypersensitivity reactions (urticaria, angioedema, or
anaphylaxis; post-vaccination days 0–3 only), new-onset autoim-
mune disease (immune thrombocytopenic purpura [ITP], hemoly-
tic anemia), type 1 diabetes, and Kawasaki disease. We identified
all outcomes by ICD-9 diagnostic codes. We monitored for all
deaths during the study period using state records.
2.3. Chart reviews
We conducted medical record chart review for all pre-specified
outpatient outcomes listed above in order to verify the diagnosis
and determine the timing of onset. We also conducted chart
reviews for outcomes for which the analyses revealed an elevated
incidence rate ratio (IRR) and for which either biologic plausibility
or a temporal relationship suggested a possible relationship to vac-
cination. Study investigators assessed relatedness and biologic
plausibility through electronic medical record review.
2.4. Subject grouping
We categorized all vaccinees into 6 groups according to the
brand of DTaP received (Table 1). Group 1 included children whoreceived only DTaP-IPV/Hib vaccine for doses 1–4. Groups 2–5
included children who only received a specific single brand of DTaP
vaccine other than DTaP-IPV/Hib. Group 2 received only Daptacel
(Sanofi Pasteur) for doses 1–4; Group 3 received only Tripedia
(Sanofi Pasteur) for doses 1–3, and either Tripedia vaccine or
DTaP-Hib (TriHIBit, Sanofi Pasteur) for Dose 4; Group 4 received
only Infanrix (GlaxoSmithKline); Group 5 received only
DTaP-hepatitis B virus-IPV vaccine (DTaP-HBV-IPV, Pediarix,
GlaxoSmithKline) for doses 1–3, and either Pediarix or Infanrix
vaccine for Dose 4; Group 6 children received a mixture of DTaP
brands for the 4 doses (i.e., more than one brand of DTaP) or the
brand was unknown for at least one dose.
2.5. Statistical analyses
We used the multi-level Healthcare Cost and Utilization Project
(HCUP) coding structure to organize outcomes hierarchically into
meaningful groups by body systems and condition categories [4].
We calculated IRRs and 95% Confidence Intervals (CIs) for all out-
comes. Although an IRR was not calculable when there were no
events during the control interval, a lower bound for the IRR was
calculable and was considered to be significantly elevated when
it was greater than one. We also performed additional review to
further characterize outcomes for which analyses indicated a
potential increased risk. No adjustments were made for multiple
comparisons.
2.6. Risk-interval cohort analyses
The primary analysis was a risk-interval analysis in Group 1
children. This method has been utilized in similar post-licensure
vaccine safety studies [5–11] and compares rates of events during
days 0–30 post-vaccination (risk interval) with rates of events dur-
ing days 31–60 post-vaccination (comparison interval). As
described above, we calculated IRRs and 95% Confidence Intervals
(CIs) for all outcomes. For seizures and hypersensitivity reactions,
we assessed events during the 0–3 day risk interval compared with
those during the 31–60 day comparison interval. For analyses of all
doses combined, we aggregated the day 0–30 (or day 0–3 as appro-
priate) risk intervals following each dose. For all analyses, we cen-
sored person-time at the time of subsequent vaccine dose
administered prior to post-vaccination day 61.
2.7. Between-cohort analyses
Secondary analyses compared outcomes between groups
(‘‘between-cohort analyses”). We compared incidence of outcomes
during the 0–30 day risk interval in Group 1 with those during the
0–30 day risk interval in the other groups. Due to small numbers of
subjects in Groups 2–4, our main secondary analysis focused on
4174 J. Hansen et al. / Vaccine 34 (2016) 4172–4179the comparisons between Group 1 and Group 5. We also compared
Group 1 with Group 6 (crossover), and Groups 1–5 (aggregated)
with Group 6.2.8. Supplemental analyses
By-dose analyses: We performed by-dose analyses comparing
outcomes within 30 days after each dose of DTaP-IPV/Hib for both
the risk-interval and between-cohort analyses. All subjects were
considered ‘‘pure” at Dose 1 but subjects could ‘‘crossover” at a
successive dose, at which point they would join Group 6 for that
dose and all subsequent doses. For example, an infant who
received DTaP-IPV/Hib vaccine for Dose 1 followed by DTaP-HBV-
IPV vaccine for Dose 2 would be included in Group 1 for the
dose-1 by-dose analysis, Group 6 for the dose-2 by-dose analysis,
and Group 6 in the all-doses-combined analysis.
Group 1 sub-analyses: We stratified Group 1 into those who
received DTaP-IPV/Hib with and without concomitant rotavirus
vaccine.
Group 6 sub-analyses: We analyzed Group 6 stratified to those
who received DTaP-IPV/Hib for Doses 1–3 but a different DTaP
for Dose 4, and to those who received non-DTaP-IPV/Hib vacci-
nes for Doses 1–3 but DTaP-IPV/Hib for Dose 4.
This study was approved by the KPNC Institutional Review
Board. The ClinicalTrials.gov Identifier is NCT00804284.3. Results
Subject accrual occurred between October 1, 2008 and July 31,
2010. In Group 1, there were a total of 14,042 subjects who
received 1 dose of DTaP-IPV/Hib vaccine, 13,194 who received 2
doses, 12,548 who received 3 doses, and 6702 who received 4
doses. The largest comparison group, Group 5 DTaP-HBV-IPV recip-
ients, had a total of 46,634 subjects who received 1 dose of
DTaP-HBV-IPV, 43,893 who received 2 doses, 41,367 who received
3 doses and 28,481 who received 4 doses. Approximately 29% of
study subjects received a different Dose 4 than of the DTaP series
they started. Demographic and racial characteristics were gener-
ally similar between the groups, although those in Groups 2 and
4 tended to be older at age of first dose and Group 5 had a smaller
percentage of subjects who were white race (supplemental table
online). There were no subjects who met pre-specified criteria for
categorization into Group 3 because neither Tripedia nor TriHIBit
vaccine were used at KPNC during the study period. Overall, the
seasonality of vaccination was similar across the groups and across
all doses.
Receipt of concomitant vaccines was generally similar between
the combination DTaP vaccine groups (Groups 1 and 5 for Doses
1–3); however, due to the greater variability in vaccines adminis-
tered at 12–15 months, no calculation for Dose 4 was performed
(data for concomitant vaccine percentages not shown).3.1. ED and hospital analyses
Including all inpatient, ED, and outpatient outcomes among all
analyses (i.e., Doses 1–4 individually, first 3, and 4 doses com-
bined), we performed a total of 58,640 IRR calculations, of which
166 were significantly elevated and 165 were significantly
decreased (these 331 calculations represented 100 HCUP cate-
gories). When we analyzed only specific doses (i.e., doses 1–4 indi-
vidually), 70 IRRs were significantly elevated and 67 were
significantly decreased.In the primary Group 1 risk-interval analysis, including all set-
tings and all doses of DTaP-IPV/Hib (either individual doses or all
doses combined), 20 HCUP categories were significantly elevated
(Table 2) and 12 HCUP categories were significantly decreased
(data not shown). Of these, we reviewed the medical records of
cases during the risk interval in three HCUP categories: skin and
subcutaneous tissue infections; symptoms, signs and ill-defined
conditions, and factors influencing health status; and fever of
unknown origin. None of the reviews suggested a relationship with
DTaP-IPV/Hib (Table 4).
Secondary analyses compared events 30 days post-vaccination
between Group 1 and Group 5 (DTaP-HBV-IPV) and demonstrated
comparable ED and hospital outcomes. Analyses of individual
doses and all doses combined revealed 32 significantly elevated
HCUP categories (Table 3) and 20 significantly decreased HCUP cat-
egories (data not shown). We reviewed medical records for the fol-
lowing HCUP categories that occurred significantly more often
after DTaP-IPV/Hib: respiratory failure, diseases of the genitouri-
nary system, other complications of surgical and medical proce-
dures, poisoning by other medications and drugs, and
lymphadenitis (Table 4). One case of lymphadenitis occurred at
the site of a vaccine administered concomitantly with DTaP-IPV/
Hib and was considered potentially related to receipt of the con-
comitant vaccine. None of the outcomes were considered related
to DTaP-IPV/Hib.
Comparing Group 1 with Group 6 (crossover group) yielded
similar findings to those seen both in the primary Group 1 and
the secondary Group 1 versus Group 5 analyses, with the addition
that acute and chronic tonsillitis (HCUP category 8.1.3) was
increased after DTaP-IPV/Hib in the hospital setting. Medical
record review did not suggest a relationship to DTaP-IPV/Hib
(Table 4).3.2. Pre-specified outcomes
There were no significantly elevated pre-specified outcomes in
the outpatient setting after DTaP-IPV/Hib. There were 3 cases of
hypersensitivity (urticaria) in 2 subjects that were considered
related to DTaP-IPV/Hib, although there were significantly fewer
hypersensitivity reactions in Group 1 (N = 2) compared with Group
2 (N = 1; IRR 0.31, 95% CI 0.002–0.927). Four subjects experienced 5
seizures within 72 h after vaccination that were considered related
to DTaP-IPV/Hib. There were no cases of Guillain-Barré Syndrome,
encephalitis, or meningitis during the 30-day risk interval after
DTaP-IPV/Hib in the outpatient setting, and none of the diagnoses
of alteration of consciousness or encephalopathy were considered
related to DTaP-IPV/Hib. There were no cases of ITP or type 1
diabetes in the outpatient setting during the risk interval after
DTaP-IPV/Hib. There was 1 case of hemolytic anemia and 2 cases
of Kawasaki disease after DTaP-IPV/Hib; none were considered
related to DTaP-IPV/Hib.3.3. Supplemental analyses
Outcomes with significantly elevated IRRs identified in ‘‘by
dose” analyses were included in either the primary Group 1 risk-
interval analysis (Table 2) or secondary Group 1 versus Group 5
analysis (Table 3). Results from the Group 1 risk-interval analysis
stratified by receipt of rotavirus vaccine were similar to the pri-
mary analysis with the exception of an increased IRR for acute
upper respiratory infections (HCUP 8.1.5.1; IRR 8.80, 95% CI
1.45–194.50). This outcome was not investigated further since
HCUP categories for respiratory infections (HCUP 8.1) and other
upper respiratory infections (HCUP 8.1.5) were significantly
reduced in several other analyses, including the primary analysis.
Table 2
Outcomes that were significantly elevated during the 30 days after vaccination among subjects who only received DTaP-IPV/Hib (Group 1).
Outcome description (HCUP code) Setting Dose Risk interval days 0–30 Comparison interval days
31–60
IRR (95% CI)
Events
(N)
Rate/1000 person-
months
Events
(N)
Rate/1000 person-
months
Infectious and parasitic diseases (1) Hospital 2 5 0.38 0 0.00 NE (1.12, NE)
Hypovolemia (3.8.2) Hospital 1 7 0.50 0 0.00 NE (1.69, NE)
Hypovolemia (3.8.2) Hospital Any
4a
10 0.31 2 0.07 4.70 (1.15,
31.57)
Diseases of the respiratory system (8) Hospital 1 36 2.56 15 1.18 2.17 (1.20,
4.08)
Other lower respiratory disease (8.8) Hospital 1 12 0.85 1 0.08 10.86 (1.88,
234.21)
Other and unspecified lower respiratory disease (8.8.3) Hospital 1 12 0.85 1 0.08 10.86 (1.88,
234.21)
Diseases of the genitourinary system (10) ED 4 6 0.90 0 0.00 NE (1.50, NE)
Genitourinary symptoms and ill-defined conditions (10.1.8) ED Any
4a
6 0.19 0 0.00 NE (1.45, NE)
Genitourinary symptoms and ill-defined conditions (10.1.8) ED First
3b
6 0.25 0 0.00 NE (1.44, NE)
Diseases of the skin and subcutaneous tissue (12) ED 4 11 1.65 3 0.46 3.57 (1.06,
15.95)
Skin and subcutaneous tissue infections (12.1) ED 4 6 0.90 0 0.00 NE (1.50, NE)
Cardiac and circulatory congenital anomalies (14.1) Hospital 2 6 0.45 0 0.00 NE (1.42, NE)
Certain conditions originating in the perinatal period (15) ED 1 19 1.35 6 0.47 2.87 (1.18,
7.84)
Certain conditions originating in the perinatal period (15) ED Any
4a
16 0.50 5 0.17 3.01 (1.14,
9.19)
Other perinatal conditions (15.7) ED 1 19 1.35 6 0.47 2.87 (1.18,
7.84)
Other perinatal conditions (15.7) ED Any
4a
16 0.50 5 0.17 3.01 (1.14,
9.19)
Other and unspecified perinatal conditions (15.7.4) ED 1 12 0.85 3 0.24 3.62 (1.09,
15.99)
Other and unspecified perinatal conditions (15.7.4) ED Any
4a
10 0.31 0 0.00 NE (2.69, NE)
Other and unspecified perinatal conditions (15.7.4) Hospital Any
4a
5 0.16 0 0.00 NE (1.15, NE)
Other and unspecified perinatal conditions (15.7.4) ED First
3b
8 0.33 0 0.00 NE (2.05, NE)
Injury and poisoning (16) Hospital 2 8 0.61 1 0.08 7.36 (1.18,
164.60)
Injury and poisoning (16) Hospital 4 5 0.75 0 0.00 NE (1.19, NE)
Injury and poisoning (16) Hospital Any
4a
18 0.56 5 0.17 3.39 (1.31,
10.22)
Fractures (16.2) Hospital Any
4a
6 0.19 0 0.00 NE (1.45, NE)
Fractures (16.2) Hospital First
3b
5 0.21 0 0.00 NE (1.14, NE)
Skull and face fractures (16.2.2) ED Any
4a
5 0.16 0 0.00 NE (1.15, NE)
Skull and face fractures (16.2.2) Hospital Any
4a
5 0.16 0 0.00 NE (1.15, NE)
Symptoms; signs; and ill-defined conditions and factors
influencing health status (17)
ED 2 89 6.76 51 4.21 1.61 (1.14,
2.28)
Symptoms; signs; and ill-defined conditions (17.1) ED 2 81 6.15 41 3.38 1.82 (1.26,
2.67)
Fever of unknown origin (17.1.2) ED 2 50 3.79 25 2.06 1.84 (1.15,
3.02)
Nausea and vomiting (17.1.6) ED 1 16 1.14 5 0.39 2.89 (1.10,
8.83)
ED = Emergency Department; NE = Not Evaluable; CI = Confidence Interval; IRR = Incidence Rate Ratio.
a ‘‘Any 4” included post-vaccination outcomes combined across all doses that a subject received (up to 4).
b ‘‘First 3” refers to post-vaccination outcomes combined across the first 3 doses of DTaP-IPV/Hib.
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received DTaP-IPV/Hib for Doses 1–3 and a different DTaP for Dose
4 detected 2 additional outcomes with significantly elevated IRRs
(genitourinary congenital anomalies [HCUP category 14.3; IRR
4.08, 95% CI 1.25–17.86] and nausea and vomiting [HCUP category
17.1.6; IRR 2.12, 95% CI 1.09–4.33]); neither outcome was explored
further because of a lack of biological plausibility for genitourinary
congenital anomalies, and because nausea and vomiting was
already investigated as part of HCUP 17 (Symptoms; signs; andill-defined conditions and factors influencing health status). Group
6 analyses that were restricted to those who received 3 doses of
the same DTaP for doses 1–3 and then DTaP-IPV/Hib for Dose 4
detected a significantly elevated IRR for the outcome of diseases
of the nervous system and sense organs (HCUP 6; IRR 3.73, 95%
CI 1.58–10.04), an increase which derived entirely from elevations
in the related subcategories of convulsions (HCUP 6.4.2; IRR 5.83,
95% CI 1.47–38.41) and suppurative and unspecified otitis media
(HCUP 6.8.1.1; IRR 3.56, 95% CI 1.06–15.91).
Table 3
Outcomes that were significantly elevated during the 30 days after vaccination comparing DTaP-IPV/Hib subjects (Group 1) with DTaP-HBV-IPV subjects (Group 5).
Outcome description (HCUP code) Setting Dose Group 1 interval days 0–30 Group 5 interval days 0–30 IRR (95% CI)
Events
(N)
Rate/1000 person-
months
Events
(N)
Rate/1000 person-
months
Substance-related disorders (5.12) Hospital Any
4a
2 0.06 0 0.00 NE (1.20, NE)
Substance-related disorders (5.12) Hospital First
3b
2 0.08 0 0.00 NE (1.20, NE)
Other paralysis (6.3.2) Hospital 3 3 0.24 1 0.02 9.89 (1.05,
260.34)
Inflammation; infection of eye (except that caused by TB
or STD) (6.7.5)
ED First
3b
12 0.50 23 0.23 2.17 (1.04, 4.32)
Other central nervous system disorders (6.9.2) Hospital 3 3 0.24 1 0.02 9.89 (1.05,
260.32)
Respiratory failure (8.6.1) Hospital 4 2 0.30 0 0.00 NE (1.22, NE)
Diseases of the genitourinary system (10) ED 2 15 1.14 23 0.52 2.17 (1.11, 4.15)
Diseases of the genitourinary system (10) Hospital 3 21 1.67 33 0.80 2.10 (1.20, 3.62)
Diseases of the genitourinary system (10) ED Any
4a
30 0.94 71 0.53 1.76 (1.13, 2.68)
Diseases of the genitourinary system (10) ED First
3b
23 0.96 57 0.57 1.68 (1.02, 2.70)
Diseases of the urinary system (10.1) ED 1 13 0.92 19 0.41 2.27 (1.09, 4.61)
Diseases of the urinary system (10.1) ED Any
4a
23 0.72 56 0.42 1.71 (1.03, 2.75)
Diseases of the urinary system (10.1) ED First
3b
20 0.83 48 0.48 1.73 (1.01, 2.89)
Other and unspecified diseases of kidney and ureters
(10.1.6.2)
ED Any
4a
2 0.06 0 0.00 NE (1.20, NE)
Other and unspecified diseases of kidney and ureters
(10.1.6.2)
ED First
3b
2 0.08 0 0.00 NE (1.20, NE)
Genitourinary symptoms and ill-defined conditions
(10.1.8)
ED 2 3 0.23 1 0.02 9.98 (1.06,
262.73)
Genitourinary symptoms and ill-defined conditions
(10.1.8)
ED Any
4a
6 0.19 5 0.04 4.99 (1.46,
17.77)
Genitourinary symptoms and ill-defined conditions
(10.1.8)
ED First
3b
6 0.25 3 0.03 8.30 (2.07,
40.63)
Other and unspecified genitourinary symptoms (10.1.8.3) ED Any
4a
3 0.09 1 0.01 12.47 (1.33,
328.39)
Other and unspecified genitourinary symptoms (10.1.8.3) ED First
3b
3 0.12 1 0.01 12.45 (1.33,
327.73)
Diseases of male genital organs (10.2) Hospital 3 15 1.19 18 0.43 2.75 (1.36, 5.49)
Diseases of male genital organs (10.2) ED Any
4a
8 0.25 11 0.08 3.02 (1.16, 7.60)
Other male genital disorders (10.2.3) Hospital 3 15 1.19 18 0.43 2.75 (1.36, 5.49)
Other skin and subcutaneous infections (12.1.2) ED 4 2 0.30 0 0.00 NE (1.22, NE)
Other inflammatory condition of skin (12.2) ED First
3b
2 0.08 0 0.00 NE (1.20, NE)
Acquired deformities (13.6) Hospital First
3b
2 0.08 0 0.00 NE (1.20, NE)
Other acquired deformities (13.6.2) Hospital First
3b
2 0.08 0 0.00 NE (1.20, NE)
Congenital anomalies (14) Hospital 3 40 3.19 85 2.05 1.55 (1.06, 2.25)
Congenital anomalies (14) ED 4 2 0.30 0 0.00 NE (1.22, NE)
Other upper gastrointestinal congenital anomalies (14.2.8) Hospital First
3b
3 0.12 1 0.01 12.45 (1.33,
327.74)
Genitourinary congenital anomalies (14.3) Hospital 3 29 2.31 34 0.82 2.81 (1.70, 4.63)
Genitourinary congenital anomalies (14.3) Hospital Any
4a
28 0.87 56 0.42 2.08 (1.31, 3.26)
Genitourinary congenital anomalies (14.3) Hospital First
3b
23 0.96 40 0.40 2.39 (1.41, 3.97)
Hypospadias and epispadias (14.3.2) Hospital 3 11 0.88 10 0.24 3.63 (1.51, 8.79)
Hypospadias and epispadias (14.3.2) Hospital First
3b
8 0.33 9 0.09 3.69 (1.37, 9.81)
Other congenital anomalies of genitalia (14.3.7) Hospital 3 12 0.96 13 0.31 3.04 (1.36, 6.77)
Other congenital anomalies of genitalia (14.3.7) Hospital Any
4a
11 0.34 18 0.13 2.54 (1.16, 5.37)
Other congenital anomalies of genitalia (14.3.7) Hospital First
3b
9 0.37 13 0.13 2.87 (1.18, 6.76)
Nervous system congenital anomalies (14.4) Hospital 1 7 0.50 8 0.17 2.91 (1.00, 8.26)
Spina bifida (14.4.1) Hospital Any
4a
2 0.06 0 0.00 NE (1.20, NE)
Spina bifida (14.4.1) Hospital First
3b
2 0.08 0 0.00 NE (1.20, NE)
Congenital hydrocephalus (14.4.2) Hospital First
3b
5 0.21 4 0.04 5.19 (1.31,
21.72)
Fractures (16.2) ED 3 5 0.40 4 0.10 4.12 (1.04,
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Table 3 (continued)
Outcome description (HCUP code) Setting Dose Group 1 interval days 0–30 Group 5 interval days 0–30 IRR (95% CI)
Events
(N)
Rate/1000 person-
months
Events
(N)
Rate/1000 person-
months
17.25)
Fractures (16.2) Hospital 3 3 0.24 1 0.02 9.89 (1.05,
260.33)
Fractures (16.2) Hospital Any
4a
6 0.19 8 0.06 3.12 (1.01, 9.19)
Skull and face fractures (16.2.2) Hospital Any
4a
5 0.16 5 0.04 4.16 (1.12,
15.45)
Skull and face fractures (16.2.2) Hospital First
3b
4 0.17 3 0.03 5.53 (1.14,
29.66)
Open wounds of head; neck; and trunk (16.6.1) ED 1 4 0.28 2 0.04 6.64 (1.18,
51.86)
Superficial injury; contusion (16.8) ED First
3b
24 1.00 57 0.57 1.75 (1.07, 2.80)
Other complications of surgical and medical procedures
(16.10.2.7)
Hospital 4 2 0.30 0 0.00 NE (1.22, NE)
Poisoning by other medications and drugs (16.11.2) ED 3 3 0.24 1 0.02 9.89 (1.05,
260.36)
Poisoning by other medications and drugs (16.11.2) ED 4 8 1.20 12 0.42 2.82 (1.10, 6.93)
Lymphadenitis (17.1.3) ED 3 3 0.24 0 0.00 NE (1.92, NE)
Lymphadenitis (17.1.3) ED First
3b
3 0.12 1 0.01 12.45 (1.33,
327.71)
Other aftercare (17.2.4) Hospital Any
4a
8 0.25 7 0.05 4.75 (1.67,
13.77)
Other aftercare (17.2.4) Hospital First
3b
6 0.25 5 0.05 4.98 (1.45,
17.73)
ED = Emergency Department; NE = Not Evaluable; CI = Confidence Interval; IRR = Incidence Rate Ratio.
a ‘‘Any 4” included post-vaccination outcomes combined across all doses that a subject received (up to 4).
b ‘‘First 3” refers to post-vaccination outcomes combined across the first 3 doses of DTaP-IPV/Hib.
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drome (N = 6), assault (N = 1), bronchopneumonia (N = 1),
encephalopathy (N = 1), foreign body in respiratory tree (N = 1),
malignant neoplasm of cerebrum (N = 1), pneumonia due to
parainfluenza virus (N = 1), and sepsis (N = 1). None were consid-
ered to be related to DTaP-IPV/Hib.4. Discussion
In this study, we assessed the safety of DTaP-IPV/Hib vaccine
administered to 14,042 infants who received at least one dose,
including 6703 who received a complete 4-dose series with the
vaccine as part of routine clinical care. We evaluated all ED and
hospital visits during the 30 days after vaccination and found
166 HCUP category outcomes with significantly elevated IRRs.
Although there were 165 category outcomes with significantly
reduced IRRs in ED and hospital visits, these results are not
shown because they were mainly used to put outcomes with ele-
vated IRR in context (i.e., to examine the consistency of study
findings). After reviewing the medical records of selected out-
comes in the context of biological plausibility, consistency of sig-
nal, temporal relationship, and signal strength, we identified no
unexpected safety signals after DTaP-IPV/Hib vaccination. We fur-
ther found that the safety of DTaP-IPV/Hib vaccine was compara-
ble with that of DTaP-HBV-IPV vaccine. This study provides
reassurance that DTaP-IPV/Hib was not associated with unantici-
pated safety risks.
All subjects in this study were vaccinated according to routine
clinic practice within KPNC, and the majority received either
DTaP-IPV/Hib (Group 1) or DTaP-HBV-IPV (Group 5). Subjects in
Group 2 and Group 4 also received care at the same KPNC clinics,
but their parents or physicians chose to use separate DTaP vaccines
instead of the combination vaccines that were routinely adminis-
tered at KPNC. Subjects in the DTaP-IPV/Hib and DTaP-HBV-IPV
groups had comparably high percentages of subjects who receivedthe recommended concomitant vaccines at Doses 1, 2, and 3. Indi-
viduals in Groups 2 and 4 were older at first vaccination (average
age 4.9 months versus approximately 2 months) and were less
likely to receive the recommended concomitant vaccines during
the infant series, suggesting that there were a number of important
differences between individuals in Groups 1 and 5 versus those in
Groups 2 and 4. Since there were far fewer individuals in Groups 2
and 4, and given these differences between groups, we focused our
analyses on subjects in Groups 1 and 5.
The findings from this study are similar to those of another
study [12] that used group sequential methods to compare
149,337 vaccinees of DTaP-IPV/Hib with both historical recipients
of DTaP-containing vaccines as well as current recipients of other
DTaP-containing vaccines during the same period. That study did
not find increased risk for seizure, meningitis/encephalitis/myeli
tis, non-anaphylactic serious allergic reaction, anaphylaxis,
Guillain-Barré syndrome, or invasive Hib disease. Unlike the cur-
rent study, Nelson et al., found a modest decrease in medically
attended fever in infants 6 1 year old and an increased risk in med-
ically attended fever in 1–2 year olds. As in our study, Nelson et al.,
found that the safety profile of DTaP-IPV/Hib was similar to that of
concurrent recipients of other DTaP-containing vaccines.
Before licensure in the US, the safety and immunogenicity of
DTaP-IPV/Hib vaccine was evaluated in multiple randomized clin-
ical trials in the US and Canada among more than 9500 subjects, of
whom over 7000 received this vaccine during the infant series or
toddler booster dose. The rates of injection-site and systemic reac-
tions and serious adverse events were similar to those in children
vaccinated with separately administered single-entity equivalent
vaccines [3,13,14].
In contrast to pre-licensure clinical trials that evaluate vaccine
safety among a smaller number of subjects, adverse events with
low frequencies of occurrence may escape detection or adequate
characterization until the product is used in a larger number of
individuals. Further, following licensure, vaccines are routinely
used more widely in clinical practice. A particular strength of this
Table 4
Summary of medical records reviewed for HCUP categories with elevated relative risk.
Outcome description (HCUP code) Review summary
Acute and chronic tonsillitisa (8.1.3) This category was significantly elevated in recipients of DTaP-IPV/Hib compared with crossover subjects
(Group 6). There were three cases that consisted of hypertrophy of adenoids on days 4 and 11, and
hypertrophy of tonsil with adenoids on day 26 post-vaccination. On investigator review, these were found to
be unrelated to receipt of any vaccine
Respiratory failure (8.6.1) There were two cases of inpatient respiratory failure in the risk interval. The first was admitted 26 days after
vaccination due to pneumonia and the second was admitted 9 days after vaccination due to seizure with
fever, breathing difficulty, and hernia protrusion. Based on investigator review of each case, neither event was
considered to have been related to receipt of DTaP-IPV/Hib, but the latter case may have potentially been
related to MMRV
Diseases of the genitourinary system (10) 14/30 cases were in the UTI category and were evenly distributed throughout the 30 day risk interval. The
timing ranged between day 1 and day 29, with the mean on day 16. The remaining 16 cases were: balanitis/
balanoposthitis (N = 3), hematuria (N = 2), phimosis (N = 2), acquired hydrocele (N = 1), acute pyelonephritis
(N = 1), chronic renal insufficiency (N = 1), dysuria (N = 1), penile discharge (N = 1), penis edema (N = 1),
proteinuria (N = 1), urinary retention (N = 1), vesicoureteral reflux (N = 1). Based on investigator review of
these disparate outcomes, they were not investigated further and were determined to have an unlikely
relationship to receipt of DTaP-IPV/Hib
Diseases of the urinary system (10.1) 14/23 cases in this group were the same UTI cases described above and these cases led to the elevated risk in
this category. The 14 cases were more likely to be seen after the first and second doses: 7 cases after Dose 1, 3
cases after Dose 2, 2 cases after Dose 3, and 2 cases after Dose 4
Skin and subcutaneous tissue infections (12.1) This outcome underwent further investigation because it was elevated in the primary analysis as well as in
supplementary analyses (i.e., elevated after any DTaP-IPV/Hib dose when compared with other pure groups
combined; data not shown). There were 11 cases in this larger category as follows: cellulitis and abscess of
neck (N = 1, day 18), cellulitis and abscess of upper arm and forearm (N = 1, day 11), cellulitis and abscess of
buttock (N = 3, between days 13 and 19), cellulitis and abscess of foot except toes (N = 1, day 7), impetigo
(N = 1, day 19), pilonidal cyst without mention of abscess (N = 3, between days 16 and 30), and Unspecified
local infection of the skin and subcutaneous tissue (N = 1, day 27). Details about location where specified and
the timing of these infections did not suggest a relationship to vaccination or the injection site
Other complications of surgical and medical
procedures (16.10.2.7)
There were two cases in this group. The first was hospitalized 30 days after DTaP-IPV/Hib (and concomitant
vaccines) and available records indicate that the infant had a vomiting episode associated with two seizures
while overseas. The treating physicians indicated the illness was due to norovirus but without confirmation.
The second case was hospitalized 26 days after DTaP-IPV/Hib (and concomitant vaccines). This infant was one
of the 8.6.1 Respiratory failure cases described above. This category was not investigated further
Poisoning by other medications and drugs (16.11.2) There were a total of 11 cases combined after the 3rd and 4th doses. Of these, one that was after the 4th dose
of DTaP-IPV/Hib was determined by the study investigator (Klein) possibly to be related to receipt of
DTaP-IPV/Hib. It consisted of an approximate 3  4 cm flat area of erythema near the injection site that was
diagnosed as ‘‘Vaccines adverse reaction”. Of the remaining 10 cases, 3 occurred after the 3rd dose and 7 after
the 4th dose of DTaP-IPV/Hib. Those after the 3rd dose had the following diagnoses: accidental possible
amlodipine ingestion (day 7); possible cigarette ingestion (day 6), and a child who developed a rash after
taking amoxicillin for otitis media (day 6). The 7 cases after the 4th dose were related to ingestions or
medication reactions: rash after sulfamethoxazole and trimethoprim (day 7), unknown ingestion when found
with grandparent’s pill container (day 20), ingestion of parent’s anti-depressants (day 26), possible ingestion
of lisinopril (day 15), onion ingestion (day 30), overdosing of heart medication (day 20), and ingestion of blue
fluid from a popped squeeze toy (day 12)
Symptoms; signs; and ill-defined conditions and
factors influencing health status (17)
This is a broad category but most cases involved fever (discussed below under HCUP 17.1.2). The largest two
categories of non-fever events were ‘‘Nausea with vomiting” and ‘‘Vomiting alone” of which there were 16
total cases. The range of days was from the day 1 to day 18. The mean days for medical attention were 11 and
6, respectively, or 8.6 when the two categories are combined. Additionally, one sub-category was allergic
reactions of which there were four cases, two of which were determined by the investigator to be related to
receipt of DTaP-IPV/Hib (both being cases of urticaria beginning on the day of vaccination)
Fever of unknown origin (17.1.2) There were 50 cases that were distributed evenly throughout the 30-day risk interval. There was no apparent
relationship with DTaP-IPV/Hib vaccination
Lymphadenitis (17.1.3) There were 3 cases of lymphadenitis, occurring on days 9, 17 and 20 after DTaP-IPV/Hib. One case occurred at
the injection site of a different vaccine and was considered as potentially related to the concomitant vaccine.
On investigator review, the remaining two cases were considered to be unrelated to any vaccine
a Acute and chronic tonsillitis (8.1.3) was not significantly elevated in the primary self-control analysis (Table 2) or in the secondary analysis of DTaP-IPV/Hib versus DTaP-
HBV-IPV (Table 3). This category was significantly elevated in a secondary analysis that compared recipients of DTaP-IPV/Hib with crossover subjects (Group 6).
4178 J. Hansen et al. / Vaccine 34 (2016) 4172–4179study was our ability to introduce DTaP-IPV/Hib vaccine into the
KPNC health plan and subsequently follow infants vaccinated as
part of routine clinical care. Another strength was our ability to
investigate potential safety findings by easily accessing medical
records, which allowed for in-depth review of the clinical histories
and detail of the course and timing of illness for selected subjects.
Finally, an important strength of this study was the comparison of
outcomes after DTaP-IPV/Hib with those following other DTaP-
containing vaccines, particularly DTaP-HBV-IPV; neither the pri-
mary nor secondary analyses detected any safety outcomes, which
provide support for the conclusion that DTaP-IPV/Hib was not
associated with new safety concerns.
This study had limitations. Although we reviewed most safety
concerns that arose in this study, review of all potential outcomeevents was not feasible for safety surveillance of this scale. We
therefore limited our efforts to investigating outcomes that were
both elevated statistically and for which there was some biological
plausibility. We were also not able to always differentiate between
outcomes which occurred acutely post-vaccination and those
which occurred prior to vaccination (i.e., ‘‘history of” diagnoses)
without medical record review. However, we believe that our use
of differing comparison periods and vaccine groups minimized
potential biases that could be associated with such misclassifica-
tion. Further, the DTaP vaccine type administered was mostly
based on clinic preference and it was conceivable that differences
in practice between clinics could influence study findings between
groups. Finally, this study was not large enough in size to detect
rare outcomes.
J. Hansen et al. / Vaccine 34 (2016) 4172–4179 4179In conclusion, the safety of DTaP-IPV/Hib was comparable with
other DTaP-containing vaccines used in this age group. The study
did not detect any safety signals following DTaP-IPV/Hib and pro-
vides reassurance that DTaP-IPV/Hib administered as part of rou-
tine care is not associated with unexpected safety concerns.
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